ES2036199T3 - Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal. - Google Patents

Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.

Info

Publication number
ES2036199T3
ES2036199T3 ES198787112412T ES87112412T ES2036199T3 ES 2036199 T3 ES2036199 T3 ES 2036199T3 ES 198787112412 T ES198787112412 T ES 198787112412T ES 87112412 T ES87112412 T ES 87112412T ES 2036199 T3 ES2036199 T3 ES 2036199T3
Authority
ES
Spain
Prior art keywords
procedure
obtaining
pharmaceutical preparation
administrable pharmaceutical
body membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787112412T
Other languages
English (en)
Inventor
Majid Mahjour
Uma Iyer
Mahdi B. Fawzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25413211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2036199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2036199T3 publication Critical patent/ES2036199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA APLICACION DESCRIBE UNA COMPOSICION ADMINISTRABLE QUE CONSTA DE: A) ENTRE UN 0,2 % Y UN 5% DE UN AGENTE BIOACTIVO, B) ENTRE UN 1% Y UN 20% DE UN COMPONENTE GRASO, Y C) ENTRE UN 80 Y UN 99% DE UN COMPONENTE SECUNDARIO. TAMBIEN SE DESCRIBE EL PROCEDIMIENTO PARA SU PREPARACION.
ES198787112412T 1986-08-27 1987-08-26 Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal. Expired - Lifetime ES2036199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/900,865 US4908389A (en) 1986-08-27 1986-08-27 Penetration enhancement system

Publications (1)

Publication Number Publication Date
ES2036199T3 true ES2036199T3 (es) 1993-05-16

Family

ID=25413211

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787112412T Expired - Lifetime ES2036199T3 (es) 1986-08-27 1987-08-26 Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.

Country Status (8)

Country Link
US (1) US4908389A (es)
EP (1) EP0261429B1 (es)
JP (1) JPS63126832A (es)
AT (1) ATE53301T1 (es)
CA (1) CA1316825C (es)
DE (1) DE3763011D1 (es)
ES (1) ES2036199T3 (es)
GR (1) GR3000536T3 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788064A (en) * 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5164406A (en) * 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
WO1991002553A2 (en) * 1989-08-17 1991-03-07 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
DK0497919T3 (da) * 1989-10-23 1997-06-09 Theratech Inc Iontoforesenordning, der anvender en hastighedsstyrende membran
AR246186A1 (es) * 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
US5324521A (en) * 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
AU653156B2 (en) * 1990-06-14 1994-09-22 Dermamed Transdermal administration to humans and animals
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
TW206152B (es) * 1991-03-20 1993-05-21 Kuko Seiyaku Kk
GB9109965D0 (en) * 1991-05-07 1991-07-03 Unilever Plc Cosmetic composition
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
WO1995009007A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
ATE214702T1 (de) * 1997-09-25 2002-04-15 Lohmann Therapie Syst Lts Säureadditionssalze von morphin-alkaloiden und deren verwendung
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU5404399A (en) * 1998-09-10 2000-04-03 Ipr-Institute For Pharmaceutical Research Ag Topical application products
ES2372592T3 (es) * 1999-04-08 2012-01-24 Intercell Usa, Inc. Formulación seca para la inmunización transcutánea.
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
JP2005504002A (ja) * 2001-02-13 2005-02-10 ガバメント オブ ザ ユナイテッド ステイツ、 アズ リプリゼンティッド バイ ザ セクレタリィ オブ ジ アーミイ 経皮免疫感作のためのワクチン
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
GB0218811D0 (en) * 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2377932T3 (es) 2003-10-10 2012-04-03 Ferring Bv Formulación farmacéutica transdérmica para minimizar los residuos sobre la piel
US20080139507A1 (en) * 2004-08-26 2008-06-12 Bioderm Research Method of Treating Skin Condition Including Acne, Skin Aging, Body Odor & Diaper Rash by Zinc Zeolite Clathrates
US20070166255A1 (en) * 2004-11-22 2007-07-19 Gupta Shyam K Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006070653A1 (ja) * 2004-12-27 2006-07-06 Lion Corporation 皮膚外用剤組成物
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
EP2004297A2 (en) * 2006-04-04 2008-12-24 The Trustees of Columbia University in the City of New York Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
NO343857B1 (no) * 2006-07-18 2019-06-24 Meda Ab Immunresponsmodifiserende skumformuleringer
WO2008016475A2 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
CA2683436C (en) * 2007-04-11 2016-07-26 John A. Mccarty Melatonin tablet and methods of preparation and use
CN101896175B (zh) * 2007-12-12 2013-03-13 帝国制药株式会社 含有环氧洛芬的水性贴剂
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
EP0095813A3 (en) * 1982-06-01 1985-05-08 THE PROCTER & GAMBLE COMPANY Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch

Also Published As

Publication number Publication date
US4908389A (en) 1990-03-13
ATE53301T1 (de) 1990-06-15
DE3763011D1 (de) 1990-07-12
GR3000536T3 (en) 1991-07-31
EP0261429A1 (en) 1988-03-30
EP0261429B1 (en) 1990-06-06
JPS63126832A (ja) 1988-05-30
CA1316825C (en) 1993-04-27

Similar Documents

Publication Publication Date Title
ES2036199T3 (es) Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.
NO870241D0 (no) Hypoglykemiske tiazolidindioner.
ZA895090B (en) Novel benzopyran derivatives,processes for their preparation and their use and preparations containing the compounds
NO157212C (no) Fremgangsmaate for fremstilling av belegg med lav emisjonsevne.
GR3005035T3 (es)
AU7546887A (en) Variants of lav viruses, their dna- and protein-components and their uses, particularly for diagnostic purposes and for the preparation of immunogenic compositions
IE822648L (en) 7-oxabicycloheptane and 7-oxabicycloheptene compounds.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
ES512894A0 (es) "un procedimiento para obtener de orina una fraccion que contiene un ingrediente antineoplastico de naturaleza peptidica".
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
NO166281C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,1-disubstituerte cyklopropanderivater.
NO883750D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
NO910874D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
JPS52139713A (en) Sustained release cefalexin preparations
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
ATE55985T1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
NO873514L (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive forbindelser.
ZA874470B (en) New tetrahydrobenzothiazoles,and the preparation and use thereof
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
JPS53127432A (en) Novel physiologically active substance, anthglutin, and its preparation
ES2023670B3 (es) Procedimiento de preparacion de una mezcla que contiene ciclohexanol y ciclohexanona a partir de ciclohexano.
JPS53127808A (en) Preparation of human albumin
JPS52111576A (en) Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 261429

Country of ref document: ES